DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Read Disclaimer

Fulgent Genetics (FLGT) Stock Analysis Report Q3 2025 | Technical Analysis | Merlintrader

? FULGENT GENETICS (NASDAQ: FLGT)

Complete Stock & Technical Analysis | Q3 2025 Financial Results | 12-Month Timeline

? Executive Summary

Fulgent Genetics, Inc. (NASDAQ: FLGT) operates a dual-business model: (1) Laboratory Services — precision diagnostics representing 80%+ of revenue, and (2) Therapeutic Development — novel cancer drugs. Q3 2025 results massively beat expectations: Revenue $84.1M (+17% YoY) vs estimate $81.4M, and non-GAAP EPS $0.14 vs consensus -$0.22 — a $0.36 positive surprise. Company raised FY 2025 guidance to $325M revenue.

Lead therapeutic FID-007 showed 51% objective response rate (ORR) in Phase 2 for head and neck cancer — best-in-class efficacy. Analyst consensus is BUY led by UBS (Strong Buy $30), Raymond James (Buy $25). Stock rallied +66% YTD to $30.15.

PRICE
$30.15
UBS TARGET
$30
CASH
$814.6M
MARKET CAP
$932M

? Ming Hsieh — Founder, Chairman & CEO

  • Born 1956 in Shenyang, China — Survived Cultural Revolution. Father was electrical engineer.
  • USC Education: B.S. Electrical Engineering (1983), M.S. (1984)
  • Cogent Systems (1990-2010): Co-founded world leader in biometric identification. Acquired by 3M for ~$1 billion (2010). IPO 2004, ranked #1 by BusinessWeek.
  • National Academy of Engineering (2015): Elected at age 59 — rare honor for engineering innovation
  • Fulgent Genetics (2011-present): Founded after 3M exit. CEO, owns ~10% (~$184M)
  • USC Benefactor: Endowed $35M to establish Ming Hsieh Department of Electrical Engineering (2006). Additional $50M for Ming Hsieh Institute for Cancer Engineering-Medicine (2010)

? Q3 2025 Verified Financial Results

MetricActualConsensusBeat
Core Revenue$84.1M$81.4M+$2.7M ✓
Non-GAAP EPS$0.14-$0.22+$0.36 ✓
Gross Margin44.3%~41%+330 bps ✓
YoY Revenue Growth+17%+15% est.Exceeded ✓

? 12-Month Timeline (Nov 2024 – Nov 2025)

Feb 28, 2025
FY 2024 Results: Full-year revenue $258.5M. 2025 guidance: $310M revenue, $0.00 EPS. Stock ~$18-19.
May 1, 2025
Q1 2025 Results: Revenue $73.5M (+16% YoY). Non-GAAP EPS $0.04. Cash $814.6M.
Aug 5, 2025
UBS UPGRADES TO STRONG BUY from Neutral. Target price $30. Major catalyst. Stock +18%
Oct 17-21, 2025
ESMO 2025: FID-007 Phase 2 data shows 51% ORR combined arms. Best-in-class efficacy. Stock +15%
Nov 7, 2025
Q3 2025 MASSIVE BEAT: Revenue $84.1M vs $81.4M. EPS $0.14 vs -$0.22 (+$0.36 surprise). Raised FY guidance to $325M. Stock +22%
Nov 27, 2025
Current Status: Stock $30.15 near 52-week high $31.04. YTD rally +66%. UBS Strong Buy $30, RJ Buy $25.

? Top-Tier Analyst Ratings

AnalystRatingTargetDate
UBS (Lu Li)STRONG BUY$30Aug 5, 2025
Raymond James (A. Cooper)BUY$25May 2025
Piper Sandler (D. Westenberg)HOLD$30Nov 10, 2025

? BULL CASE

  • 51% ORR best-in-class in head/neck cancer
  • Q3 EPS beat +$0.36 — massive surprise
  • 17% revenue growth, accelerating
  • 44.3% gross margin expanding
  • UBS Strong Buy — institutional conviction
  • $814.6M cash — no dilution risk
  • Ming Hsieh aligned — 10% owner, proven track record

? BEAR CASE

  • FID-007 still Phase 2 — execution risk
  • GAAP losses $21.3M Q3 despite beat
  • Diagnostics mature market — high competition
  • Stock +66% YTD — valuation extended
  • Customer concentration disclosed
  • Insider selling in late Nov
  • Piper Sandler Hold — cautious tone

? Technical Analysis

Daily Chart (Finviz)

FLGT Daily Chart Finviz

Key Technical Levels

LevelPriceTypeSignificance
52-Week High$31.04ResistanceCurrent $30.15 near this level
52-Week Low$14.57SupportStrong base, +106% from low
200-Day MA~$22.30SupportLong-term trend bullish
50-Day MA~$27.50SupportRecent consolidation zone
Resistance Target$32.50BreakoutNext level if breaks $31.04

Chart Pattern Analysis

  • Pattern: Ascending channel with consolidation (Nov 2024 – Nov 2025)
  • Trend: Strong uptrend (+66% YTD) — price above all major moving averages
  • RSI (14): 68-72 range — approaching overbought territory
  • MACD: Positive histogram above signal line — uptrend intact
  • Volume: Q3 earnings spike with high volume confirms institutional buying

Trading Scenarios & Probabilities

ScenarioTriggerTargetProbability
BULLISH BREAKOUTBreak above $31.04 on high volume$35-3840%
BEARISH BREAKDOWNClose below $27.50 (50-day MA)$22-2435%
SIDEWAYS CONSOLIDATIONRange-bound $28-31$29.50 ± $1.5025%

Key Technical Indicators

IndicatorReadingSignalInterpretation
RSI (14)68-72OverboughtPullback possible
MACDPositive histogramBullishUptrend confirmed
ADX (14)40+Strong TrendMomentum confirmed
Volume TrendDeclining on ralliesWeakeningCaution warranted

Technical Levels to Watch

SignalEntry PriceDescription
LONG$28-29Buy on dip at support level
SHORT$31.50Sell at resistance level
BREAKOUT$31.04+Break above 52-week high

? Upcoming Catalysts (2025-2027)

  • Q4 2025: FY 2025 full results (Feb 2026). FID-007 Phase 2 enrollment completion
  • H1 2026: FID-007 Phase 2 topline data. Potential Accelerated Approval pathway
  • 2026+: Phase 2b/3 initiation, partnership deals, expanded clinical data
  • Strategic: M&A target given $814M cash and clinical pipeline

? Sources & References

All data sourced from official SEC filings, company press releases, and tier-1 financial institutions:

  1. SEC Edgar — Fulgent Genetics Inc. Official Filings
  2. NASDAQ — Fulgent Q3 2025 Financial Results (Nov 7, 2025)
  3. Business Wire — Fulgent Q4 2024 Results (Feb 2025)
  4. BioSpace — ESMO 2025 FID-007 Data Presentation (Oct 20, 2025)
  5. StockAnalysis — FLGT Analyst Ratings & Price Targets
  6. Wikipedia — Ming Hsieh: Cogent Systems Founder, Fulgent CEO
  7. USC Ming Hsieh Institute — Ming Hsieh Biography
  8. USC Viterbi — Ming Hsieh Electrical Engineering Pioneer (Nov 2024)

⚠️ IMPORTANT LEGAL DISCLAIMER — EDUCATIONAL PURPOSES ONLY:

This report is provided solely for informational and educational purposes and does NOT constitute investment advice, a recommendation to buy or sell any security, or an offer of financial services. The information contained herein is based on sources believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results. All investments carry inherent risk, including possible loss of principal.

Biotech & Small-Cap Risk: Fulgent Genetics (FLGT) is a biotech company with material risks: (1) Clinical trial failure — FID-007 Phase 2 data is positive but Phase 2b/3 trials may fail or show negative results; (2) Regulatory setbacks — FDA may deny approval, request additional studies, or impose restrictions; (3) Competitive pressure — larger diagnostics companies (Quest Diagnostics, LabCorp, Illumina) have scale and resources; (4) Execution risk — management may fail to execute strategy; (5) Market volatility — biotech stocks experience extreme price swings unrelated to fundamentals.

Technical Analysis Limitations: Technical analysis is not predictive. Chart patterns, indicators (RSI, MACD, etc.), and price levels are historical observations and may not indicate future price movements. Technical analysis should never be the sole basis for investment decisions. Current RSI reading (68-72) suggests overbought conditions, but this does not guarantee a pullback — stock can remain overbought for extended periods.

Valuation & Market Conditions: FLGT stock has rallied +66% YTD. Analyst consensus is BUY with target $30 (already achieved), but consensus can be wrong. Market sentiment shifts rapidly; what is “buy” today may be “sell” tomorrow. Sector rotation (biotech out of favor), macro conditions (interest rates, recession fears), or company-specific events (insider selling, guidance misses) can trigger sharp drawdowns.

Not Financial Advice: This report is NOT a substitute for professional financial, investment, or tax advice. You should conduct your own due diligence and consult with qualified financial advisors, investment professionals, and tax specialists before making any investment decisions. Merlintrader, its authors, and affiliates do not manage accounts, provide portfolio advice, or have fiduciary relationships with readers. Any reliance on this information is at your own risk.

Risk Management: If you choose to trade or invest in FLGT, use strict risk management: (1) Position sizing — limit positions to small % of portfolio; (2) Stop losses — always use stop losses to limit downside; (3) Do not invest money you cannot afford to lose; (4) Diversify — do not concentrate bets on single stocks; (5) Monitor holdings regularly; (6) Be prepared for 20-30% pullbacks even in bullish scenarios.

Data & Accuracy: Financial data sourced from SEC filings (10-Q, 10-K), official company press releases, and verified financial databases. While efforts have been made to ensure accuracy, errors may occur. Always verify key figures with primary sources before acting. Stock price ($30.15) and analyst ratings are accurate as of November 28, 2025, but are subject to change.

Conflicts of Interest Disclosure: Merlintrader may have affiliate relationships with brokerages, financial platforms, or data providers mentioned in this report. This report is published without compensation from Fulgent Genetics or any related parties. However, potential conflicts should be considered when evaluating this information.

Updated: November 28, 2025 | Next Update: Following Q4 2025 earnings (Feb 2026) or material company events

? FULGENT GENETICS (NASDAQ: FLGT)

Analisi Stock & Tecnica Completa | Risultati Finanziari Q3 2025 | Timeline 12 Mesi

? Analisi Esecutiva

Fulgent Genetics, Inc. (NASDAQ: FLGT) opera con modello dual-business: (1) Laboratory Services — diagnostica precisione (80%+ ricavi), e (2) Therapeutic Development — farmaci cancro innovativi. Q3 2025 beat massicciamente: Ricavi $84.1M (+17% YoY vs stima $81.4M), non-GAAP EPS $0.14 vs consenso -$0.22 — sorpresa +$0.36. Alzata guida FY 2025 a $325M ricavi.

Farmaco principale FID-007 mostrato 51% ORR in Phase 2 per cancro testa/collo — efficacia best-in-class. Consenso analista BUY con UBS (Strong Buy $30), Raymond James (Buy $25). Azione rally +66% YTD a $30.15.

PREZZO
$30.15
UBS TARGET
$30
CASSA
$814.6M
MARKET CAP
$932M

? Ming Hsieh — Founder, Chairman & CEO

  • Nato 1956 a Shenyang, China — Sopravvissuto Rivoluzione Culturale. Padre ingegnere.
  • USC Education: B.S. Ingegneria Elettrica (1983), M.S. (1984)
  • Cogent Systems (1990-2010): Co-founder leader mondiale biometric. Acquisito 3M ~$1 miliardo (2010).
  • National Academy of Engineering (2015): Eletto età 59 — raro onore innovazione
  • Fulgent Genetics (2011-present): Fondato dopo exit 3M. CEO, 10% owner (~$184M)
  • Benefattore USC: Donati $35M per Dipartimento Ingegneria (2006). $50M Ming Hsieh Institute Cancer Medicine (2010)

? Top-Tier Analyst Ratings

AnalistaRatingTargetData
UBSSTRONG BUY$30Ago 5, 2025
Raymond JamesBUY$25Mag 2025
Piper SandlerHOLD$30Nov 10, 2025

? Analisi Tecnica

Grafico Daily (Finviz)

FLGT Grafico Daily Finviz

Livelli Tecnici da Osservare

SegnaleEntry PriceDescrizione
LONG$28-29Buy on dip at support
SHORT$31.50Sell at resistance
BREAKOUT$31.04+Break above 52-week high

⚠️ IMPORTANTE DISCLAIMER LEGALE — SCOPI EDUCATIVI SOLO:

Questo report è fornito esclusivamente a scopi informativi ed educativi e NON costituisce consulenza investimento, raccomandazione buy/sell, o offerta servizi finanziari. Informazioni contenute basate su fonti ritenute affidabili ma non garantite per accuratezza o completezza. Performance passata non indica risultati futuri. Tutti gli investimenti comportano rischio intrinseco, inclusa possibile perdita capitale.

Rischio Biotech & Small-Cap: FLGT è azienda biotech con rischi materiali: (1) Fallimento trial clinica — dati FID-007 Phase 2 positivi ma Phase 2b/3 può fallire; (2) Setback regulatory — FDA può negare approvazione; (3) Pressione competitiva — competitor più grandi hanno scala; (4) Rischio esecuzione — management può fallire strategie; (5) Volatilità mercato — azioni biotech hanno swing estremi.

Limitazioni Analisi Tecnica: Analisi tecnica non è predittiva. Pattern grafici e indicatori (RSI, MACD) sono osservazioni storiche, non garantiscono movimenti futuri. RSI 68-72 suggerisce ipercomprato ma non garantisce pullback — azione può rimanere ipercomprata.

Non è Consulenza Finanziaria: Questo report NON sostituisce consulenza finanziaria professionale. Consultare advisor qualificati prima decisioni investimento. Merlintrader non gestisce account, non ha relazioni fiduciarie. Qualsiasi affidamento informazione è vostro rischio.

Aggiornato: 28 novembre 2025